A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed or refractory diffuse large B-cell lymphoma who had previously received rituxi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Haematologica
Main Authors: Trnĕný, Marek, Verhoef, Gregor, Dyer, Martin JS, Ben Yehuda, Dina, Patti, Caterina, Canales, Miguel, Lopez, Andrés, Awan, Farrukh T, Montgomery, Paul G, Janikova, Andrea, Barbui, Anna M, Sulek, Kazimierz, Terol, Maria J, Radford, John, Guidetti, Anna, Di Nicola, Massimo, Siraudin, Laure, Hatteville, Laurence, Schwab, Sandrine, Oprea, Corina, Gianni, Alessandro M
Format: Artigo
Sprog:Inglês
Udgivet: Ferrata Storti Foundation 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6068033/
https://ncbi.nlm.nih.gov/pubmed/29748443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.168401
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker